Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Arbutus Biopharma Corporation
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 01, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
July 18, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
June 06, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
June 05, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Participate in Jefferies Global Healthcare Conference
May 29, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Present Imdusiran Data at EASL Congress 2024
May 22, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Participate in Two Upcoming Investor Conferences
May 07, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 02, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
May 02, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
April 18, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
April 04, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Participate in Two Upcoming Investor Conferences
March 08, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 29, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
February 15, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
January 08, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
November 09, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
BRNS
Arbutus to Present at Jefferies London Healthcare Conference
November 08, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
November 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
October 24, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
October 18, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
October 11, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
September 11, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Participate in Two Upcoming Investor Conferences
September 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
August 03, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
July 20, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
July 12, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Arbutus Appoints Two New Executives
July 10, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
BMY
KRYS
NBRV
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
June 21, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
VACC
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
June 21, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Tickers
ABUS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.